No Data
A-shares fluctuated丨The Concept of influenza continues to weaken, Shandong Lukang Pharmaceutical dropped over 7%, and the Chinese Center for Disease Control and Prevention stated that the positive rate of influenza virus has recently shown a tendency to s
On January 10, according to Gelonghui, A-share flu concept stocks continue to adjust. Among them, Shandong Lukang Pharmaceutical fell over 7%, Shanghai Kaibao Pharmaceutical dropped over 6%, Xiangxue Pharmaceutical decreased by 4.6%, and Guangdong Zhongsheng Pharmaceutical, Shanghai Kehua Bio-engineering, Dirui Industrial, and Hunan Er-kang Pharmaceutical also fell. In news, the China Center for Disease Control and Prevention released the latest situation on national sentinel surveillance of acute respiratory infectious diseases. The recent positive rate of influenza virus has slowed down, and it is expected that the level of influenza activity will gradually decline in mid to late January, with different levels of influenza activity in various provinces. Among them, the positive rates of rhinovirus, adenovirus, and mycoplasma pneumonia continue to decline. Other respiratory pathogens, such as the novel coronavirus, remain at a low epidemic level.
Express News | Pharma stocks rebounded in the morning, with Guangdong Hybribio Biotech soaring nearly 14%, while Tellgen Corporation, West Point Pharmaceutical, and Shandong Lukang Pharmaceutical strengthened in the short term.
Express News | Shandong Lukang Pharmaceutical: The issuance of A-shares to specific targets has been approved by Hualu Holding Group Co., Ltd.
A-shares flu Concept stocks are pulling back: Xiangxue Pharmaceutical has fallen over 7%, while Shandong Lukang Pharmaceutical briefly dropped 4%.
On January 7, Gelonghui reported that the flu Concept stocks, which had previously surged, collectively adjusted. Among them, Xiangxue Pharmaceutical decreased by over 7%, Apeloa Pharmaceutical and Shanghai Kaibao Pharmaceutical fell by over 5%, while Guilin Layn Natural Ingredients Corp., Zhejiang Hisun Pharmaceutical, Shijiazhuang Yiling Pharmaceutical, and Guangdong Zhongsheng Pharmaceutical saw declines of over 2%. Shandong Lukang Pharmaceutical opened high and at one point fell to 4%, previously recording two consecutive trading limit ups.
Shandong Lukang Pharmaceutical (600789.SH): Currently, there have been no significant changes in the product structure and main Business.
On January 6, Gelonghui reported that Shandong Lukang Pharmaceutical (600789.SH) announced that on January 2, January 3, and January 6, 2025, the cumulative closing price increase deviation of the company's stocks exceeded 20% over two consecutive trading days. According to the relevant provisions of the Shanghai Stock Exchange Trading Rules, this constitutes an abnormal fluctuation in stock trading. The company's main business includes the research and development, production, and sales of pharmaceutical products. The company's products mainly involve systemic anti-infective agents, cardiovascular, digestive system, endocrine, andrology, respiratory, and veterinary agricultural antibiotics, among others. The current product structure and main business are both ...
A-shares midday review: Chinext Price Index rises by 0.41%, flu Concept stocks are active, and the CSI Consumer 360 index sectors are experiencing a decline.
As of the midday close, the Shanghai Composite Index fell by 0.15% to 3206.75 points, the Shenzhen Component Index rose by 0.19%, and the Chinext Price Index increased by 0.41%.